Literature DB >> 19122791

Sensitivity Analyses Comparing Time-to-Event Outcomes Existing Only in a Subset Selected Postrandomization.

Bryan E Shepherd1, Peter B Gilbert, Thomas Lumley.   

Abstract

In some randomized studies, researchers are interested in determining the effect of treatment assignment on outcomes that may exist only in a subset chosen after randomization. For example, in preventative human immunodeficiency virus (HIV) vaccine efficacy trials, it is of interest to determine whether randomization to vaccine affects postinfection outcomes that may be right-censored. Such outcomes in these trials include time from infection diagnosis to initiation of antiretroviral therapy and time from infection diagnosis to acquired immune deficiency syndrome. Here we present sensitivity analysis methods for making causal comparisons on these postinfection outcomes. We focus on estimating the survival causal effect, defined as the difference between probabilities of not yet experiencing the event in the vaccine and placebo arms, conditional on being infected regardless of treatment assignment. This group is referred to as the always-infected principal stratum. Our key assumption is monotonicity-that subjects randomized to the vaccine arm who become infected would have been infected had they been randomized to placebo. We propose nonparametric, semiparametric, and parametric methods for estimating the survival causal effect. We apply these methods to the first Phase III preventative HIV vaccine trial, VaxGen's trial of AIDSVAX B/B.

Entities:  

Keywords:  Acquired immune deficiency syndrome; Causal inference; Kaplan–Meier; Principal stratification

Year:  2007        PMID: 19122791      PMCID: PMC2613336          DOI: 10.1198/016214507000000130

Source DB:  PubMed          Journal:  J Am Stat Assoc        ISSN: 0162-1459            Impact factor:   5.033


  12 in total

Review 1.  Challenges and opportunities for development of an AIDS vaccine.

Authors:  G J Nabel
Journal:  Nature       Date:  2001-04-19       Impact factor: 49.962

Review 2.  Clinical trials of HIV vaccines.

Authors:  Barney S Graham
Journal:  Annu Rev Med       Date:  2002       Impact factor: 13.739

3.  Principal stratification in causal inference.

Authors:  Constantine E Frangakis; Donald B Rubin
Journal:  Biometrics       Date:  2002-03       Impact factor: 2.571

4.  Causal inference on the difference of the restricted mean lifetime between two groups.

Authors:  P Y Chen; A A Tsiatis
Journal:  Biometrics       Date:  2001-12       Impact factor: 2.571

5.  Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials.

Authors:  Peter B Gilbert; Ronald J Bosch; Michael G Hudgens
Journal:  Biometrics       Date:  2003-09       Impact factor: 2.571

6.  Sensitivity analyses comparing outcomes only existing in a subset selected post-randomization, conditional on covariates, with application to HIV vaccine trials.

Authors:  Bryan E Shepherd; Peter B Gilbert; Yannis Jemiai; Andrea Rotnitzky
Journal:  Biometrics       Date:  2006-06       Impact factor: 2.571

7.  An analytic method for randomized trials with informative censoring: Part 1.

Authors:  J M Robins
Journal:  Lifetime Data Anal       Date:  1995       Impact factor: 1.588

8.  Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

Authors:  Neil M Flynn; Donald N Forthal; Clayton D Harro; Franklyn N Judson; Kenneth H Mayer; Michael F Para
Journal:  J Infect Dis       Date:  2005-01-27       Impact factor: 5.226

9.  On the analysis of viral load endpoints in HIV vaccine trials.

Authors:  Michael G Hudgens; Antje Hoering; Steven G Self
Journal:  Stat Med       Date:  2003-07-30       Impact factor: 2.373

10.  Causal inference in infectious diseases.

Authors:  M E Halloran; C J Struchiner
Journal:  Epidemiology       Date:  1995-03       Impact factor: 4.822

View more
  13 in total

1.  Sensitivity Analysis of Per-Protocol Time-to-Event Treatment Efficacy in Randomized Clinical Trials.

Authors:  Peter B Gilbert; Bryan E Shepherd; Michael G Hudgens
Journal:  J Am Stat Assoc       Date:  2013-01-01       Impact factor: 5.033

2.  Principal stratification--uses and limitations.

Authors:  Tyler J Vanderweele
Journal:  Int J Biostat       Date:  2011-07-11       Impact factor: 0.968

3.  Randomization-Based Inference within Principal Strata.

Authors:  Tracy L Nolen; Michael G Hudgens
Journal:  J Am Stat Assoc       Date:  2011-06       Impact factor: 5.033

4.  A simple method for principal strata effects when the outcome has been truncated due to death.

Authors:  Yasutaka Chiba; Tyler J VanderWeele
Journal:  Am J Epidemiol       Date:  2011-02-25       Impact factor: 4.897

5.  Sensitivity analyses comparing time-to-event outcomes only existing in a subset selected postrandomization and relaxing monotonicity.

Authors:  Bryan E Shepherd; Peter B Gilbert; Charles T Dupont
Journal:  Biometrics       Date:  2010-11-29       Impact factor: 2.571

6.  Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials.

Authors:  Peter B Gilbert; James O Berger; Donald Stablein; Stephen Becker; Max Essex; Scott M Hammer; Jerome H Kim; Victor G Degruttola
Journal:  J Infect Dis       Date:  2011-04-01       Impact factor: 5.226

7.  Rank-based principal stratum sensitivity analyses.

Authors:  X Lu; D V Mehrotra; B E Shepherd
Journal:  Stat Med       Date:  2013-05-19       Impact factor: 2.373

8.  Comparing competing risk outcomes within principal strata, with application to studies of mother-to-child transmission of HIV.

Authors:  Dustin M Long; Michael G Hudgens
Journal:  Stat Med       Date:  2012-08-28       Impact factor: 2.373

9.  Latent Class Survival Models Linked by Principal Stratification to Investigate Heterogenous Survival Subgroups Among Individuals With Early-Stage Kidney Cancer.

Authors:  Brian L Egleston; Robert G Uzzo; Yu-Ning Wong
Journal:  J Am Stat Assoc       Date:  2016-10-07       Impact factor: 5.033

10.  A Sequential Phase 2b Trial Design for Evaluating Vaccine Efficacy and Immune Correlates for Multiple HIV Vaccine Regimens.

Authors:  Peter B Gilbert; Douglas Grove; Erin Gabriel; Ying Huang; Glenda Gray; Scott M Hammer; Susan P Buchbinder; James Kublin; Lawrence Corey; Steven G Self
Journal:  Stat Commun Infect Dis       Date:  2011-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.